Literature DB >> 30334176

Should Pyloric Lymph Nodes Be Dissected for Siewert Type II and III Adenocarcinoma of the Esophagogastric Junctions: Experience from a High-Volume Center in China.

Huihua Cao1, Marie Ooi2, Zhan Yu1, Qing Wang1, Zhong Li1, Qicheng Lu3, Yugang Wu4.   

Abstract

BACKGROUND: The optimal extent of lymph node (LN) dissection remains controversial in adenocarcinoma of the esophagogastric junction (AEG), especially in Siewert types II and III. The aim of this study was to analyze clinicopathological characteristics of patients with Siewert type II and III AEGs to clarify whether pyloric (no. 5 and no.6) lymphadenectomy is essential in these patients.
METHODS: A retrospective analysis was performed in the Third Affiliated Hospital of Soochow University from September 2008 to December 2012, and clinicopathological characteristics on all patients with Siewert type II and III AEGs, who underwent curative total gastrectomy with lymphadenectomy were collected. The index of estimated benefit from lymph node dissection (IEBLD) was used to evaluate the efficacy of lymph node dissection of no. 5 and no. 6. Both clinicopathological characteristics and IEBLDs were set as the standards in the assessment of the value of pyloric lymph nodes dissection.
RESULTS: A total of 216 patients with AEG (Siewert type II: 141, Siewert type III: 75) were included into the study. Type III AEG had a larger tumor size and relatively advanced T stage compared to Type II AEG. The 5-year overall survival (OS) rates in type II and type III AEGs were almost similar (type II 50.4% vs. type III 46.7%, p = 0.782). There was a very low incidence of pyloric lymph nodes metastases in type II AEG (no. 5 is 1.4% and no. 6 is 0.7%). Hence, the IEBLDs of no. 5 and no. 6 lymph node were negligible regardless of the T stage and tumor differentiation. In type III AEG, metastasis rates of no. 5 and no. 6 lymph node were 9.3 and 5.3%, respectively. The IEBLDs of no. 5 and no. 6 lymph node were 2.7 and 1.3, respectively.
CONCLUSIONS: Based on the IEBLDs of pyloric lymph nodes, dissection of no. 5 and no. 6 lymph nodes were worthwhile for Siewert type III AEG but not essential for Siewert type II AEG.

Entities:  

Keywords:  Adenocarcinoma of the esophagogastric junction; Lymphadenectomy; Siewert type II; Siewert type III

Mesh:

Year:  2018        PMID: 30334176     DOI: 10.1007/s11605-018-3935-2

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  25 in total

1.  Lymph node metastasis and lymphadenectomy of resectable adenocarcinoma of the esophagogastric junction.

Authors:  Xin-Zu Chen; Wei-Han Zhang; Jian-Kun Hu
Journal:  Chin J Cancer Res       Date:  2014-06       Impact factor: 5.087

2.  Esophagojejunal anastomosis leakage after total gastrectomy for esophagogastric junction adenocarcinoma: options of treatment.

Authors:  Fabio Carboni; Mario Valle; Orietta Federici; Giovanni Battista Levi Sandri; Ida Camperchioli; Rocco Lapenta; Daniela Assisi; Alfredo Garofalo
Journal:  J Gastrointest Oncol       Date:  2016-08

Review 3.  Function-preserving surgery for gastric cancer: current status and future perspectives.

Authors:  Souya Nunobe; Naoki Hiki
Journal:  Transl Gastroenterol Hepatol       Date:  2017-09-25

4.  Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction.

Authors:  Jiang-Wei Xiao; Zi-Lin Liu; Peng-Cheng Ye; Ya-Jun Luo; Zhi-Ming Fu; Qin Zou; Shou-Jiang Wei
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

5.  Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period.

Authors:  H S Ahn; H-J Lee; M-W Yoo; S-H Jeong; D-J Park; H-H Kim; W H Kim; K U Lee; H-K Yang
Journal:  Br J Surg       Date:  2011-02       Impact factor: 6.939

6.  Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center.

Authors:  Shinichi Hasegawa; Takaki Yoshikawa; Haruhiko Cho; Akira Tsuburaya; Osamu Kobayashi
Journal:  World J Surg       Date:  2009-01       Impact factor: 3.352

7.  Mediastinal lymph node dissection and distal esophagectomy is not essential in early esophagogastric junction adenocarcinoma.

Authors:  In-Seob Lee; Ji-Yong Ahn; Jeong-Hwan Yook; Byung-Sik Kim
Journal:  World J Surg Oncol       Date:  2017-01-18       Impact factor: 2.754

8.  Postoperative complications and weight loss following jejunostomy tube feeding after total gastrectomy for advanced adenocarcinomas.

Authors:  Hylke J F Brenkman; Stéphanie V S Roelen; Elles Steenhagen; Jelle P Ruurda; Richard van Hillegersberg
Journal:  Chin J Cancer Res       Date:  2017-08       Impact factor: 5.087

9.  Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: A retrospective cohort study with long-term follow-up.

Authors:  Kei Hosoda; Keishi Yamashita; Hiromitsu Moriya; Hiroaki Mieno; Masahiko Watanabe
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

Review 10.  Extent of lymph node dissection for adenocarcinoma of the stomach.

Authors:  Simone Mocellin; Peter McCulloch; Hussain Kazi; Joaquin J Gama-Rodrigues; Yuhong Yuan; Donato Nitti
Journal:  Cochrane Database Syst Rev       Date:  2015-08-12
View more
  2 in total

1.  Survival Benefit of Pyloric Lymph Node Dissection for Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction Based on Tumor Diameter: A Large Cohort Study.

Authors:  Xia Lin; Zhengyan Li; Chenjun Tan; Xiaoshuang Ye; Jie Xiong; Jiajia Liu; Ao Mo; Yan Shi; Feng Qian; Peiwu Yu; Yongliang Zhao
Journal:  Front Oncol       Date:  2021-12-01       Impact factor: 6.244

2.  Feasibility of Preserving No. 5 and No. 6 Lymph Nodes in Gastrectomy of Proximal Gastric Adenocarcinoma: A Retrospective Analysis of 395 Patients.

Authors:  Xiao Yang; Yanan Zheng; Runhua Feng; Zhenggang Zhu; Min Yan; Chen Li
Journal:  Front Oncol       Date:  2022-02-28       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.